multiple myeloma/albumin

Krækjan er vistuð á klemmuspjaldið

Veldu tegund tegund

14 niðurstöður

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Multiple myeloma is characterized by the production of monoclonal immunoglobulin (Ig) proteins or protein fragments (M proteins) that have lost their function. The main aim of the study is to determine the safety and efficacy of JNJ-68284528 in various clinical settings. JNJ-68284528 is an

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

This study will evaluate participants with newly diagnosed multiple myeloma (MM) for whom hematopoietic stem cell transplant is not planned as initial therapy. The data available from other available studies suggests that addition of daratumumab with Velcade (bortezomib), lenalidomide, and

Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

This is a prospective, multicenter, non-comparative, open-label Phase II study. Daratumumab will be administered according to approved label. Approximately 57 subjects located in Greece will be enrolled in the study. Patients shall receive treatment until disease progression, physician decision,

Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

This is a multicenter, single arm, open-label phase 2 study. Approximately 38 subjects will be enrolled to receive daratumumab + dexamethasone. Treatment cycles have duration of 28 days. Subjects will receive treatment until disease progression, death, unacceptable toxicity or for a maximum of 30

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

The hypothesis is that the addition of daratumumab administered SC to standard MM regimens will improve responses compared to response data observed in completed phase 3 studies without daratumumab. Disease evaluations will include measurements of myeloma proteins, bone marrow examinations, skeletal

A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERs

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Background. Immunoglobulin light chains are classified as middle molecule uremic toxins together with β2M and parathyroid hormon. They have a mean molecular weight of 25,000 daltons for monomers (k free light chains) and approximately 50,000 daltons for dimers (lambda free light chains). Raised

Kidney Therapy for Free Light Chain Removal in Patients With Multiple Myeloma & Cast Nephropathy

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

This is an observational study performed to investigate the clinical benefit of FLC removal by KIDNEY therapy system in patients with cast nephropathy, dialysis dependent renal failure and de novo multiple myeloma. Recruitment commenced in July 2014, in total 20 patients will be recruited.

Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) in Multiple Myeloma

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

PROTOCOL SYNOPSIS - Study Type Monocentric prospective clinical trial Study Object Comparison of Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) with skeletal X-Ray and MRI of the spine for the assessment of bone disease in Multiple Myeloma (MM) Objectives Primary objective 1) To

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

PRIMARY OBJECTIVES: I. To evaluate the efficacy (overall response rate) of single agent nab-paclitaxel (Abraxane) (paclitaxel albumin-stabilized nanoparticle formulation) in patients with relapsed or refractory multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the adverse events associated with

A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

This is a Phase III, multi-center, double-blind, randomized, placebo-controlled, crossover study to evaluate the efficacy of armodafinil at a dosage of 150 mg/day for the treatment of cancer-related fatigue (CRF) in adult patients with multiple myeloma. The study consists of a screening period,

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OBJECTIVES: Primary - Compare engraftment of peripheral blood progenitor cells (PBPCs) mobilized by 2 different fixed doses of pegfilgrastim versus a by-weight dose of filgrastim (G-CSF). Secondary - Determine the ability of 2 different fixed doses of pegfilgrastim to mobilize PBPCs. - Determine the

Prevention of Contrast Nephropathy by Sodium Bicarbonate Versus Sodium Chloride and N-acetylcysteine

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

PROTOCOL Prevention of Contrast Nephropathy by Sodium Bicarbonate Versus Sodium Chloride and N-Acetylcysteine Nephrology and Cardiology Services, Shaare Zedek Medical Center, Jerusalem 1. Background and rationale The development of acute renal failure following cardiac catheterization has been

Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Hypothesis: 5 to 7 plasma exchanges in addition to conventional therapy at onset of myeloma with acute renal failure, reduces the composite outcome of death, dialysis dependence or a GFR < 30 ml/min/1.73 meter squared at 6 months. Entry Criteria: The inclusion criteria are a new diagnosis of

Skráðu þig á
facebook síðu okkar

Herbal & Natural Medicine

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum

Virkar á 55 tungumálum
Jurtalækningar studdir af vísindum
Jurtaviðurkenning eftir ímynd
Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
Lestu vísindarit sem tengjast leit þinni
Leitaðu að lækningajurtum eftir áhrifum þeirra
Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum

Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum